Ads
related to: sellas life sciences stock forecast- Fixed Income Insights
View Our Latest Fixed Income
Investment Insights.
- PracticeLab®
Resources to Help You Build Your
Business and Engage Your Clients.
- Capital Ideas Webinars
Our Brightest Minds Answer
Your Questions.
- Equity Insights
View Our Latest Equity
Investment Insights.
- Fixed Income Insights
Search results
Results From The WOW.Com Content Network
Merger with Sellas Life Sciences. In 2017, Galena Biopharma Inc. announced a merger "with privately-held oncology company Sellas Life Sciences Group Ltd. in an all-stock transaction." The combined company was Sellas Life Science Group. The newly merged companies focused on the development of novel treatments for cancer.
SELLAS Life Sciences Group Inc (NASDAQ: SLS) announced topline data from its Phase 1/2 trial of galinpepimut-S (GPS) in WT1(+) relapsed or refractory platinum-resistant advanced metastatic ovarian ...
If you own shares in SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) then it's worth thinking about how it contributes... One Thing To Remember About The SELLAS Life Sciences Group, Inc. (NASDAQ:SLS ...
Liminal BioSciences' aim to develop best or first-in-class therapies targeting indications with significant unmet needs, where a novel small molecule approach may be better suited using its drug discovery platform, specialized know-how and data-driven development plans. Liminal BioSciences is a development stage biopharmaceutical company ...
The Life Sciences Institute (LSI) is a collaborative, multidisciplinary research institution located on the campus of the University of Michigan in Ann Arbor.It encompasses 27 faculty-led teams from 13 schools and departments throughout U-M. The LSI brings together leading scientists from a variety of life science disciplines, working with a range of models systems and cutting-edge research ...
J&J raised the low end of its 2024 forecast by 5 cents and now expects an adjusted profit of $10.60 to $10.75 per share. It also increased its quarterly dividend by 4.2% to $1.24 per share.
Ads
related to: sellas life sciences stock forecast